Ionis Pharmaceuticals Inc
IONS43.000USD
-0.590-1.35%
收盘 07/03, 13:00（美东）报价延迟15分钟
6.84B总市值
亏损市盈率 TTM
关于 Ionis Pharmaceuticals Inc 公司
Ionis Pharmaceuticals, Inc. 从事核糖核酸 (RNA) 靶向治疗。该公司有五种已上市药物和一条产品线，涉及神经病学、心脏病学和其他患者需求高的领域。该公司有九种药物处于 III 期开发阶段，还有多种其他药物处于早期和中期开发阶段。该公司的产品包括 SPINRAZA、QALSODY、WAINUA、TEGSEDI 和 WAYLIVRA。SPINRAZA 用于治疗脊髓性肌萎缩症 (SMA) 患者，这是一种进行性、使人衰弱且通常致命的遗传疾病。QALSODY 是一种反义药物，用于治疗超氧化物歧化酶 1 肌萎缩侧索硬化症 (SOD1-ALS) 的成年患者，这是一种罕见的神经退行性疾病，会导致运动神经元逐渐丧失并导致死亡。 WAINUA 是一种自行注射的皮下配体结合反义 (LICA) 药物，用于治疗患有遗传性转甲状腺素介导的淀粉样变性多发性神经病 (ATTRv-PN) 的成年人。
公司简介
公司代码IONS
公司名称Ionis Pharmaceuticals Inc
上市日期May 17, 1991
成立日期1991
CEODr. Brett P. Monia, Ph.D.
员工数量1069
证券类型Ordinary Share
年结日May 17
公司地址2855 Gazelle Court
城市CARLSBAD
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92010
电话17609319200
网址https://www.ionis.com/
公司代码IONS
上市日期May 17, 1991
成立日期1991
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
48.55K
+0.86%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
32.25K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
+101.50%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
收入明细
单位: USD更新时间: 3月4日 周二
单位: USD更新时间: 3月4日 周二
FY2020
FY2019
业务USD
名称
营收
占比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
暂无数据
业务
地区
业务USD
名称
营收
占比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
股东统计
更新时间: 7月3日 周四
更新时间: 7月3日 周四
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
股东类型
持股股东
占比
Investment Advisor
67.26%
Investment Advisor/Hedge Fund
28.07%
Hedge Fund
13.12%
Research Firm
2.36%
Private Equity
1.60%
Sovereign Wealth Fund
1.08%
Pension Fund
0.93%
Individual Investor
0.81%
Bank and Trust
0.52%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
787
184.68M
116.03%
+8.73M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
2023Q1
825
136.59M
95.51%
-5.80M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
23.61M
14.84%
+924.09K
+4.07%
Mar 31, 2025
The Vanguard Group, Inc.
16.35M
10.27%
-88.61K
-0.54%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
16.18M
10.16%
+323.67K
+2.04%
Mar 31, 2025
Capital World Investors
12.36M
7.77%
+896.58K
+7.82%
Mar 31, 2025
Capital Research Global Investors
10.50M
6.6%
+10.50M
--
May 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
5.59%
+21.73K
+0.24%
Mar 31, 2025
Wellington Management Company, LLP
8.42M
5.29%
-255.73K
-2.95%
Mar 31, 2025
Bellevue Asset Management AG
7.85M
4.93%
-15.50K
-0.20%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
3.04%
-581.28K
-10.71%
Mar 31, 2025
Deep Track Capital LP
4.56M
2.87%
+2.63M
+136.01%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月2日 周三
更新时间: 7月2日 周三
机构名称
占比
ARK Genomic Revolution ETF
3.36%
Tema Neuroscience and Mental Health ETF
2.73%
Capital Group US Small and Mid Cap ETF
2.15%
Virtus LifeSci Biotech Products ETF
1.66%
SPDR S&P Biotech ETF
1.45%
Tema Cardiovascular and Metabolic ETF
1.25%
WisdomTree BioRevolution Fund
1.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
Franklin Genomic Advancements ETF
0.62%
Invesco NASDAQ Future Gen 200 ETF
0.61%
查看更多
ARK Genomic Revolution ETF
占比3.36%
Tema Neuroscience and Mental Health ETF
占比2.73%
Capital Group US Small and Mid Cap ETF
占比2.15%
Virtus LifeSci Biotech Products ETF
占比1.66%
SPDR S&P Biotech ETF
占比1.45%
Tema Cardiovascular and Metabolic ETF
占比1.25%
WisdomTree BioRevolution Fund
占比1.17%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.86%
Franklin Genomic Advancements ETF
占比0.62%
Invesco NASDAQ Future Gen 200 ETF
占比0.61%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
